Records real-world outcomes of blinatumomab use in B-cell acute lymphoblastic leukemia
Collects data on adults with B-cell acute lymphoblastic leukemia who receive blinatumomab consolidation.
Plain-language title generated from the registry record
Registry title: Blinatumomab Consolidation in Real World
Key facts
- Where
- Chicago, Jacksonville, Milwaukee, and Philadelphia, United StatesSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) on or after December 1st 2022. Data are collected from their records and surveys.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- B-ALL diagnosed on or after December 1st 2022.
- Earlier treatment
- Must not have received blinatumomab in an interventional clinical trial.
Read by machine on 9 November 2026.
Where in United States
- Northwestern UniversityChicago, United StatesTaking people
- The University Of ChicagoChicago, United StatesTaking people
- Mayo Clinic Cancer CenterJacksonville, United StatesTaking people
- Medical College of WisconsinMilwaukee, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT07117136
- Record updated
- 1 October 2026
- Original description
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.Read full original descriptionShow less
Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Inclusion: 1) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2022 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients.
Exclusion: N/A.